Crinetics Pharmaceuticals, Inc. announced that the late-breaking abstracts accepted for presentation at the Endocrine Society?s annual meeting (ENDO 2024) were released earlier than the previously announced embargoed date. The abstract for the Phase 2, open-label study of atumelnant (CRN04894), in Congenital Adrenal Hyperplasia contained summary data for four subjects at the time of submission. The company plans to present additional data from a total of six subjects in cohort 1 and additional subjects in cohort 2 at ENDO 2024.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
45.33 USD | -3.33% | +1.39% | +27.40% |
04/06 | Oppenheimer Raises Price Target on Crinetics Pharmaceuticals to $74 From $55, Maintains Outperform Rating | MT |
03/06 | Transcript : Crinetics Pharmaceuticals, Inc. - Special Call |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+27.40% | 357.47Cr | |
+40.80% | 5.37TCr | |
+35.79% | 3.89TCr | |
-8.05% | 3.88TCr | |
-8.98% | 2.73TCr | |
+10.69% | 2.59TCr | |
-16.21% | 2.03TCr | |
+31.00% | 1.28TCr | |
+28.51% | 1.22TCr | |
-1.67% | 1.2TCr |
- Stock Market
- Equities
- CRNX Stock
- News Crinetics Pharmaceuticals, Inc.
- Crinetics Pharmaceuticals Announces Early Release of ENDO 2024 Late-Breaking Abstracts